# Safety Study of Hemospan® in Prostatectomy Patients

> **NCT00425334** · PHASE2 · COMPLETED · sponsor: **Sangart** · enrollment: 20 (actual)

## Conditions studied

- Blood Loss, Surgical
- Prostate Cancer
- Surgery

## Interventions

- **DRUG:** Hemospan (MP4OX)
- **DRUG:** Ringer's lactate

## Key facts

- **NCT ID:** NCT00425334
- **Lead sponsor:** Sangart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-10
- **Final completion:** 2007-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425334, "Safety Study of Hemospan® in Prostatectomy Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00425334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*